Login to Your Account

Other News To Note

Wednesday, October 16, 2013
• Boston Therapeutics Inc., of Manchester, N.H., said it is sponsoring a research study with the University of Minnesota on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of postmeal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription